European Renal Association

The phase 3 TURING trial found rituximab slashed relapse rates in adults with minimal change disease and FSGS, offering a steroid-sparing alternative.

A recap of 3 Kidney Compass podcast episodes recorded at ERA 2025, including summaries and preview clips.

A recap of 5 studies to know from the ERA 2025 Congress, including expert perspectives.

A recent meta-analysis reveals GLP-1 RAs significantly reduce adverse kidney outcomes, highlighting their potential in chronic kidney disease management.

An analysis of the VALIANT trial provides insight into the benefits of pegcetacoplan in patients with C3G and IC-MPGN.

A deep dive into several noteworthy IgAN studies presented during the ERA 2025 Congress.

A RaDaR analysis from ERA 2025 provides insight into predictors of disease progression, outcomes in patients with Alport syndrome.

Discover groundbreaking insights on the VISIONARY trial, IgA nephropathy treatment, and the future of kidney care with expert Vlado Perkovic, MBBS, PhD.

Jonathan Barratt, MD, PhD, discusses results from an open-label trial of mezagitamab from ERA 2025.

A study presented at ERA 2025 validates the use of proteinuria as a surrogate endpoint for FSGS clinical trials.

The ACHIEVE trial found use of spironolcatone was not associated with a statistically significant reduction in cardiovascular death or hospitalization for HF.

An ERA 2025 analysis confirms empagliflozin significantly lowers acute kidney injury risk, reassuring clinicians about its safety in at-risk patients.

52-week data from the VALIANT program shed further light on the potential of pegcetacoplan in C3G and IC-MPGN.

Prespecified analysis of 320 patients in VISIONARY were presented at ERA 2025 Congress.

Brendon Neuen, MBBS, PhD, is joined by Rajiv Agarwal, MD, MS to explore the concept of simultaneous initiation of SGLT2i and nsMRA in CKD and T2D.

New data from a phase 2 and an OLE trial provide additional insight into the effects of iptacopan in IgA nephropathy.

Richard Lafeyette, MD, discusses his reaction to the phase 3 ORIGIN topline results and what it means for IgAN.

Combination therapy with finerenone and empagliflozin significantly reduces urinary albumin levels in CKD patients.

Jonathan Barratt, MD, PhD, offers perspective on how the 100-week data from ERA 25 inform the potential of zigakibart.

New 100-week data reveals zigakibart's significant efficacy and safety in reducing proteinuria for IgA nephropathy.

An overview of the 7 presentations included as late-breaking clinical trials at ERA 2025.

Brendon Neuen, MBBS, PhD, discusses 3 late breaking clinical trials being presented at ERA 2025.

Kaitlin Mayne, MBChB, discusses an analysis of the EMPA-Kidney trial examining the effects of multimorbidity, polypharmacy, and quality of life on effects of empagliflozin.

Alexandra Louise Møller, MS, PhD, discusses the results of a PROVALID analysis examining the predictive value of endotrophin levels for predicting CKD events.

Results suggest certain peroxiredoxins may be viable prognostic markers in glomerulopathies, including IgA nephropathy and membranous nephropathy.

Diagnostic tests for anemia etiology are infrequently ordered, leading to a significant majority of patients with CKD receiving inadequate treatment.

Iron administration did not increase the mortality risk of hemodialysis patients with cancer, but the safety of increasing ESA doses was not confirmed.

Brendon Neuen, MBBS, PhD, joins the podcast to discuss the latest updates in nephrology, including the landmark FLOW trial.

Jonathan Barratt, MD, discusses a matching-adjusted indirect comparison of sparsentan and irbesartan against standard of care plus optimized RASI.